Publicaciones

• —Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol. 2010;23(11):1499-506.
• —Navas M, Tam M, Di Persio J. Impact of Two-Step Laboratory Testing Procedures for C. difficile Infection on Physician Treatment Decisions. Infect Dis Clin Pract. 2013;21(2):123-125.
• —Navas M, Hall G, El Bejjani D. A case of endocarditis caused by Lactococcus garvieae and suggested methods for identification. J Clin Microbiol. 2013;51(6):1990-2.
• —Sobhanie ME, Venkat-Ramani T, Navas M, Kefalas CH, Rich MW. Widespread Microscopic Gastrointestinal Metastases: An Unusual Manifestation of Breast Cancer. Practical Gastroenterology. 2013;8:37-40.
• —Wojewoda CM, Sercia L, Navas M, Tuohy M, Wilson D, Hall GS, Procop GW, Richter SS. Evaluation of the Verigene Gram-positive blood culture nucleic acid test for rapid detection of bacteria and resistance determinants. J Clin Microbiol. 2013;51(7):2072-6.
• —Navas M, Pincus DH, Wilkey K, Sercia L, LaSalvia M, Wilson D, Procop GW, Richter SS. Identification of aerobic Gram-positive bacilli by use of Vitek MS. J Clin Microbiol. 2014;52(4):1274-7.
• —Navas ME, Jump R, Canaday DH, Wnek MD, SenGupta DJ, Bell M, McQuiston JR. Can anaerobes be acid fast? A novel, clinically relevant acid-fast anaerobe. JMM Case Reports. 2016;3(4).
• —Patel S, Navas M, Batt C, Jump RL. Oral Cryptococcosis in a Patient with Chronic Lymphocytic Leukemia. Int J Infect Dis. 2016;50:18-20. doi:10.1016/j.ijid.2016.07.008
• —Navas M, Jacobs M. Carbapenem Resistant Enterobacteriaceae, A Review for Laboratorians. Clinical Laboratory News (AACC). Enero 2016.
• —Bartley P, Santos C, Moretto V, et al., Navas M, et al. Fecal Contamination Contributes to the "Resistome" of Urban Surface Waters in Northeast Brazil. Open Forum Infect Dis. 2016;3(suppl_1):610. doi:10.1093/ofid/ofw172.473
• —Christian RLA, Donskey C, Navas M. Evaluation of a Rapid Diagnostic Assay for Early Detection of Bacteriuria. Open Forum Infect Dis. 2019;6(Suppl 2):S302.
• —Zabarsky TF, Bhullar D, Silva SY, Mana TSC, Ertle MT, Navas ME, Donskey CJ. What are the sources of exposure in healthcare personnel with coronavirus disease 2019 infection? Am J Infect Control. 2020. doi:10.1016/j.ajic.2020.08.004
• —Redmond SN, Dousa KM, Jones LD, et al., Navas ME, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleic Acid Contamination of Surfaces on a Coronavirus Disease 2019 Ward and Intensive Care Unit. Infect Control Hosp Epidemiol. 2020. PMID: 32782056.
• —Chan ER, Jones LD, Redmond SN, Navas ME, et al. Use of whole-genome sequencing to investigate a cluster of SARS-CoV-2 infections in emergency department personnel. Infect Control Hosp Epidemiol. 2021:1-3. doi:10.1017/ice.2021.208
• —Redmond SN, Jones LD, Sadri N, Schmotzer C, Navas M, et al. SARS-CoV-2 infection in vaccinated and unvaccinated healthcare personnel in a Veterans Affairs healthcare system. Infect Control Hosp Epidemiol. 2021. doi:10.1017/ice.2021.256
• —Redmond SN, Li DF, Haq M, et al., Navas M, et al. Frequent detection of SARS-CoV-2 RNA on hands and skin of patients with coronavirus disease 2019. Infect Control Hosp Epidemiol. 2021. doi:10.1017/ice.2021.403
• —Jinadatha C, Jones LD, Choi H, et al., Navas ME, et al. Transmission of SARS-CoV-2 in Inpatient and Outpatient Settings in a Veterans Affairs Health Care System. Open Forum Infect Dis. 2021;8(8):ofab328.
• —Camacho-Cordovez F, Henzel MK, Bauer L, et al., Navas ME. Bacterial urine profile and optimal urine specimen collection timing in asymptomatic chronically catheterized adults with spinal cord injuries and disorders. Am J Infect Control. 2021. doi:10.1016/j.ajic.2021.09.007
• —Jones LD, Chan ER, Zabarsky TF, Cadnum JL, Navas ME, et al. Transmission of SARS-CoV-2 on a Patient Transport Van. Clin Infect Dis. 2021.
• —Jones LD, Chan ER, Cadnum JL, Redmond SN, Navas M, et al. Investigation of a cluster of SARS-CoV-2 infections in a hospital administration building. Infect Control Hosp Epidemiol. 2022. doi:10.1017/ice.2022.45
• —Saad A, Hailes J, Jacobs MR, Navas ME. Antimicrobial Susceptibility Profile of Aerococcus urinae: Recommendations for Empirical Therapy. Infect Dis Clin Pract. 2023;31(1):e1176. doi:10.1097/IPC.0000000000001176
• —Torres-Teran M, Navas M, Kachaluba N, Meyer J, Donskey C. More harm than good? Potential benefits and unintended consequences associated with screening asymptomatic hospital admissions for SARS-CoV-2. Infect Control Hosp Epidemiol. 2023:1-2. doi:10.1017/ice.2023.73
• —Lee G, Schauner R, Burke J, et al., Navas M, et al. NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade. Front Immunol. 2023;14:1022890. doi:10.3389/fimmu.2023.1022890. PMID: 37483595.
• —O'Brien T, Boughan KM, Navas M, Ansari MQ. M-Protein Analysis Test: Effects of Combining Serum Protein Electrophoresis and Free Light Chain Assay Tests into One Order. Blood. 2023;142(Suppl 1):6759. doi:10.1182/blood-2023-190924
• —Valencia-Shelton F, Anderson N, Palavecino EL, Navas ME, Larkin PMK, She R, Filkins LM. Approaches to developing and implementing a molecular diagnostics stewardship program for infectious diseases: an ASM Laboratory Practices Subcommittee report. J Clin Microbiol. 2024;62:e00941-24. doi:10.1128/jcm.00941-24
• —Navas ME, Musoke L, Van Epps P, et al. Extragenital self-collection testing for gonorrhea and chlamydia: A feasibility study for expanding STI screening in the Veterans Health Administration. Am J Clin Pathol. 2024:aqae135. doi:10.1093/ajcp/aqae135
• —Navas ME, Siddiq S, Bauer L, et al., Donskey C. Do blood contamination reduction devices work? A single institution comparison. Infect Control Hosp Epidemiol. 2024:1-3. doi:10.1017/ice.2024.169. PMID: 39581855.
• —Nair J, Meyer J, Kachaluba N, McIlveen K, Ganjoo R, Navas ME. Shortening blood culture incubation times: Evaluation of optimal incubation time for a fully automated blood culture system in the clinical laboratory. Infect Dis Clin Pract. Aceptado para publicación, 2025.